Nemes Laszlo/iStock via Getty Images Arcellx's Anito-cel: A Promising Contender in Multiple Myeloma Therapy Arcellx (NASDAQ:ACLX) is developing cell therapies for multiple myeloma [MM], acute myeloid leukemia, and myelodysplastic syndrome. Anito-cel (formerly CART-ddBCMA), the company's flagship product, is being developed in a Phase 2 pivotal trial for relapsed or refractory MM (rrMM). My last article on Arcellx was in September, a month after the FDA lifted the partial clinical hold (limits some trial asp ...

Company Performance - Arcellx, Inc. reported a quarterly loss of $0.14 per share, significantly better than the Zacks Consensus Estimate of a loss of $0.51, and an improvement from a loss of $0.58 per share a year ago, indicating a 72.55% earnings surprise [1] - The company generated revenues of $39.26 million for the quarter ended March 2024, exceeding the Zacks Consensus Estimate by 32.55%, and up from $17.91 million in the same quarter last year [1] - Over the last four quarters, Arcellx has surpassed consensus EPS estimates three times and topped consensus revenue estimates two times [1] Market Outlook - Arcellx shares have declined approximately 5.9% since the beginning of the year, contrasting with the S&P 500's gain of 8.8% [2] - The company's future stock performance will largely depend on management's commentary during the earnings call and the sustainability of the recent earnings numbers [2][3] Earnings Estimates - The current consensus EPS estimate for the upcoming quarter is -$0.40 on revenues of $29.52 million, and for the current fiscal year, it is -$1.69 on revenues of $121.41 million [4] - The estimate revisions trend for Arcellx is mixed, resulting in a Zacks Rank 3 (Hold), suggesting the stock is expected to perform in line with the market in the near future [4] Industry Context - The Medical - Biomedical and Genetics industry, to which Arcellx belongs, is currently ranked in the top 35% of over 250 Zacks industries, indicating a favorable outlook compared to lower-ranked industries [5] - Another company in the same industry, Lumos Pharma, is expected to report a quarterly loss of $1.21 per share, reflecting a year-over-year change of -36%, with revenues projected at $0.51 million, down 26.1% from the previous year [5]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____ to _____ Commission File Number: 001-41259 ARCELLX, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 47-2855917 (State or other jurisd ...

Exhibit 99.1 Arcellx Provides First Quarter 2024 Financial Results REDWOOD CITY, Calif., May 9, 2024 (BUSINESS WIRE) — Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today reported business highlights and financial results for the first quarter ended March 31, 2024. First Quarter 2024 Financial Highlights Cash, cash equivalents, and marketable securities: As of March 3 ...

Biotech breakthrough stocks, along with the sector overall, faced significant challenges over the past two years, with venture capital drying up, shifts in the post-pandemic healthcare landscape and tighter regulatory conditions squeezing already-thin margins. However, 2024 may herald a resurgence for biotech stocks, spurred by an FDA approval spree throughout 2023. Last year, the FDA approved 55 treatment protocols that included previously unapproved ingredients or compounds, a significant increase from th ...

One stock that might be an intriguing choice for investors right now is Arcellx, Inc. (ACLX) . This is because this security in the Medical - Biomedical and Genetics space is seeing solid earnings estimate revision activity, and is in great company from a Zacks Industry Rank perspective.This is important because, often times, a rising tide will lift all boats in an industry, as there can be broad trends taking place in a segment that are boosting securities across the board. This is arguably taking place in ...

Arcellx, Inc. (ACLX) came out with quarterly earnings of $0.42 per share, beating the Zacks Consensus Estimate of a loss of $0.63 per share. This compares to loss of $0.76 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 166.67%. A quarter ago, it was expected that this company would post a loss of $0.56 per share when it actually produced a loss of $0.81, delivering a surprise of -44.64%.Over the last four quarters, the compan ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-41259 ARCELLX, INC. (Exact name of Registrant as specified in its Charter) Delaware 47-2855917 (State or other jurisdiction of (I.R.S ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 28, 2024 Arcellx, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-41259 47-2855917 (State or Other Jurisdiction (Commission File Number) (IRS Employer of Incorporation) Identification No .) 800 Bridge Parkway Suite A Redwood City, California 94065 (Address of P ...

-- Expanded strategic partnership with Kite -- -- Presented continued robust long-term responses from Phase 1 expansion trial of anito-cel (formerly CART-ddBCMA) in patients with relapsed or refractory multiple myeloma -- -- Ended the quarter with $729.2M, extending cash runway into 2027 -- REDWOOD CITY, Calif., Feb. 28, 2024 /PRNewswire/ -- Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other ...